This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aileron Therapeutics Stock (NASDAQ:ALRN) Get Aileron Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.75▼$3.9352-Week Range N/AVolume63,385 shsAverage Volume82,980 shsMarket Capitalization$45.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas. Read More Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALRN Stock News HeadlinesRodman & Renshaw sets $8 target for Rein Therapeutics stockJanuary 28, 2025 | msn.comAileron Therapeutics Rebrands As Rein TherapeuticsJanuary 10, 2025 | markets.businessinsider.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 10 at 2:00 AM | StockEarnings (Ad)Aileron Therapeutics Announces Rebranding to Rein TherapeuticsJanuary 10, 2025 | prnewswire.comWiechart speaks on Aileron's impact on his small businessJanuary 7, 2025 | yahoo.comAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | prnewswire.comAileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03November 14, 2024 | markets.businessinsider.comAileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary FibrosisNovember 14, 2024 | markets.businessinsider.comSee More Headlines ALRN Stock Analysis - Frequently Asked Questions How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.20. When did Aileron Therapeutics' stock split? Aileron Therapeutics shares reverse split on Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN). Company Calendar Last Earnings8/14/2024Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALRN CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees9Year Founded2005Profitability EPS (Trailing Twelve Months)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.08% Return on Assets-27.93% Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / BookN/AMiscellaneous Outstanding Shares21,670,000Free Float20,561,000Market Cap$45.72 million OptionableNot Optionable Beta2.24 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ALRN) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.